Zacks Research Upgrades Conexeu Sciences (NASDAQ:CNXU) to Hold

Conexeu Sciences (NASDAQ:CNXU) was upgraded by investment analysts at Zacks Research to a “hold” rating in a research report issued on Monday,Zacks.com reports.

A number of other research analysts have also recently issued reports on the stock. Wall Street Zen upgraded shares of Conexeu Sciences to a “hold” rating in a report on Saturday, May 30th. HC Wainwright assumed coverage on shares of Conexeu Sciences in a report on Monday, June 22nd. They issued a “buy” rating and a $20.00 target price on the stock. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $20.00.

Conexeu Sciences Trading Up 6.6%

Conexeu Sciences stock opened at $10.92 on Monday. Conexeu Sciences has a 1 year low of $9.60 and a 1 year high of $18.79.

Conexeu Sciences (NASDAQ:CNXU) last announced its quarterly earnings results on Monday, June 15th. The company reported ($0.11) EPS for the quarter.

Insider Activity at Conexeu Sciences

In other Conexeu Sciences news, Director Lynn Sebastian Purcell purchased 202,500 shares of the company’s stock in a transaction dated Thursday, June 18th. The shares were bought at an average price of $0.80 per share, with a total value of $162,000.00. Following the completion of the transaction, the director directly owned 2,734,240 shares in the company, valued at $2,187,392. This trade represents a 8.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Trending Headlines about Conexeu Sciences

Here are the key news stories impacting Conexeu Sciences this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $20 price target, signaling confidence in Conexeu Sciences despite near-term losses. Conexeu Sciences Free Report
• Positive Sentiment: The firm’s longer-term estimates turn sharply positive, with projected EPS of $1.02 for FY2028, $1.70 for FY2029, and $2.52 for FY2030, suggesting potential future earnings growth. Conexeu Sciences Free Report
• Neutral Sentiment: HC Wainwright’s near-term forecasts remain negative, including estimated losses of ($0.40) per share for FY2026 and ($0.53) for FY2027, which keeps investors focused on execution rather than current profitability. Conexeu Sciences Free Report

Conexeu Sciences Company Profile

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.